Mersana Therapeutics
MRSN
MRSN was delisted on the 5th of January, 2026.
29 hedge funds and large institutions have $236M invested in Mersana Therapeutics in 2017 Q2 according to their latest regulatory filings, with 29 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
74.92% more ownership
Funds ownership: 0% → 74.92% (+75%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NMC
NEA Management Company
Timonium,
Maryland
|
+$113M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
+$28.3M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$24M |
| 4 |
RSCM
Rock Springs Capital Management
Baltimore,
Maryland
|
+$21.1M |
| 5 |
PAI
ProQuest Associates IV
Naples,
Florida
|
+$13.2M |
Top Sellers
MRSN Hedge Fund Activity: Q2 2017 in Review
29 of the 4,022 institutional investors tracked by Wall St. Rank reported a position in Mersana Therapeutics (MRSN) for Q2 2017, worth a combined $236M.
Buyers outnumbered sellers: 29 funds opened new MRSN positions and 0 closed out — a net gain of 29 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was NEA Management Company, opening a new position worth an estimated $113M.
- 29 institutional investors held Mersana Therapeutics (MRSN) as of Q2 2017, up from 0 in Q1 2017.
- Funds reported $236M of Mersana Therapeutics stock for Q2 2017.
- 29 funds opened new Mersana Therapeutics positions in Q2 2017 and 0 closed out, a net change of +29 holders.
- The largest Mersana Therapeutics buyer in Q2 2017 was NEA Management Company, an estimated $113M added.
Based on aggregated 13F filings for Q2 2017.